

## Form 603

Corporations Act 2001  
Section 671B

## Notice of initial substantial holder

To: Company Name/Scheme Sirtex Medical LtdACN/ARSN 078 116 122

## 1. Details of substantial holder (1)

Name Sand Grove Capital Management LLP

ACN/ARSN (if applicable) \_\_\_\_\_

The holder became a substantial holder on 30/08/2018

## 2. Details of voting power

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in on the date the substantial holder became a substantial holder are as follows:

Class of securities (4)	Number of securities	Person's votes (5)	Voting power (6)
Ordinary (Equity CFD)	3,198,432	3,198,432*	5.73%*

\*Sand Grove Capital Management LLP holds the position (through the Sand Grove Opportunities Master Fund Ltd and the Sand Grove Tactical Fund LP) on swap (Equity CFD) and therefore will not have voting discretion.

## 3. Details of relevant interests

The nature of the relevant interest the substantial holder or an associate had in the following voting securities on the date the substantial holder became a substantial holder are as follows:

Holder of relevant interest	Nature of relevant interest (7)	Class and number of securities
Sand Grove Capital Management LLP	Acting as the investment for and on behalf of the Sand Grove Opportunities Master Fund Ltd and the Sand Grove Tactical Fund LP	Ordinary (Equity CFD) 3,198,432

## 4. Details of present registered holders

The persons registered as holders of the securities referred to in paragraph 3 above are as follows:

Holder of relevant interest	Registered holder of securities	Person entitled to be registered as holder (8)	Class and number of securities
Sand Grove Capital Management LLP	Multiple	Sand Grove Opportunities Master Fund Ltd	Ordinary (Equity CFD) 2,960,735
Sand Grove Capital Management LLP	Multiple	Sand Grove Tactical Fund LP	Ordinary (Equity CFD) 237,696

## 5. Consideration

The consideration paid for each relevant interest referred to in paragraph 3 above, and acquired in the four months prior to the day that the substantial holder became a substantial holder is as follows:

Holder of relevant interest	Date of acquisition	Consideration (9)		Class and number of securities
		Cash	Non-cash	
attached				

**6. Associates**

The reasons the persons named in paragraph 3 above are associates of the substantial holder are as follows:

Name and ACN/ARSN (if applicable)	Nature of association
Sand Grove Opportunities Master Fund Ltd	Sand Grove Capital Management LLP acts as the investment manager
Sand Grove Tactical Fund LP	Sand Grove Capital Management LLP acts as the investment manager

**7. Addresses**


The addresses of persons named in this form are as follows:

Name	Address
Sand Grove Capital Management LLP	35 Dover Street, London, W1S 4NQ

**Signature**

print name **Penelope Brudenell-Brude** capacity **Head of Operations & Financing**

sign here



date **30/08/2018**

**DIRECTIONS**

- (1) If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 7 of the form.
- (2) See the definition of "associate" in section 9 of the Corporations Act 2001.
- (3) See the definition of "relevant interest" in sections 603 and 671B(7) of the Corporations Act 2001.
- (4) The voting shares of a company constitute one class unless divided into separate classes.
- (5) The total number of votes attached to all the voting shares in the company or voting interests in the scheme (if any) that the person or an associate has a relevant interest in.
- (6) The person's votes, divided by the total votes in the body corporate or scheme multiplied by 100.
- (7) Include details of:
  - (a) any relevant agreement or other circumstances by which the relevant interest was acquired. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
  - (b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).

See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.
- (8) If the substantial holder is unable to determine the identity of the person (eg. if the relevant interest arises because of an option) write "unknown".
- (9) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.

## Holders of relevant interest

Trade Date	Nature of change	Consideration	Number of securities	Issue Price	Class
16-May-18	Purchase	12,259,298.55	242,717.00	29.7552	Ordinary (Equity CFD)
16-May-18	Purchase	1,449,506.00	35,000.00	29.79	Ordinary (Equity CFD)
17-May-18	Purchase	2,641,838.37	88,036.00	29.7811	Ordinary (Equity CFD)
17-May-18	Purchase	2,222,890.21	68,948.00	29.7728	Ordinary (Equity CFD)
18-May-18	Purchase	1,383,905.75	45,345.00	29.1907	Ordinary (Equity CFD)
18-May-18	Purchase	4,329,416.27	151,323.00	29.1903	Ordinary (Equity CFD)
21-May-18	Purchase	4,785,286.26	158,641.00	29.8497	Ordinary (Equity CFD)
22-May-18	Purchase	35,845.03	1,126.00	29.5015	Ordinary (Equity CFD)
22-May-18	Purchase	58,182,657.15	893,500.00	28.5789	Ordinary (Equity CFD)
24-May-18	Purchase	614,473.79	21,250.00	28.9356	Ordinary (Equity CFD)
25-May-18	Purchase	18,202,822.08	620,805.00	29.4866	Ordinary (Equity CFD)
30-May-18	Purchase	6,638,192.52	207,337.00	29.1226	Ordinary (Equity CFD)
31-May-18	Purchase	1,384,477.30	13,248.00	29.248	Ordinary (Equity CFD)
01-Jun-18	Purchase	1,170,490.41	39,717.00	29.4685	Ordinary (Equity CFD)
04-Jun-18	Purchase	930,556.40	31,268.00	29.7227	Ordinary (Equity CFD)
05-Jun-18	Purchase	1,585,387.65	23,728.00	29.6801	Ordinary (Equity CFD)
06-Jun-18	Purchase	3,884,781.99	124,201.00	29.1477	Ordinary (Equity CFD)
18-Jun-18	Purchase	469,595.87	25,126.00	31.0821	Ordinary (Equity CFD)
19-Jun-18	Purchase	816,497.30	26,144.00	31.2371	Ordinary (Equity CFD)
27-Jun-18	Rep	14,968,042.09	472,505.00	31.4608	Ordinary (Equity CFD)
03-Jul-18	Purchase	7,118,627.32	67,309.00	31.38	Ordinary (Equity CFD)
27-Aug-18	Purchase	7,894,858.48	65,252.00	31.1697	Ordinary (Equity CFD)
28-Aug-18	Purchase	96,584.17	3,836.00	31.8703	Ordinary (Equity CFD)
29-Aug-18	Purchase	3,371,878.28	73,277.00	37.1397	Ordinary (Equity CFD)
29-Aug-18	Purchase	8,550,000.00	250,500.00	32.16	Ordinary (Equity CFD)
29-Aug-18	Purchase	5,208,400.00	177,500.00	32.16	Ordinary (Equity CFD)
30-Aug-18	Purchase	159,500.00	5,000.00	31.80	Ordinary (Equity CFD)
30-Aug-18	Purchase	6,716,600.00	186,000.00	31.88	Ordinary (Equity CFD)
30-Aug-18	Purchase	6,372,800.00	208,000.00	31.80	Ordinary (Equity CFD)
30-Aug-18	Purchase	9,827,200.00	320,000.00	31.80	Ordinary (Equity CFD)